Charles Q. Morris
Chief Tech/Sci/R&D Officer at LAVA THERAPEUTICS N.V.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Allen Hurly | M | 56 | 5 years | |
| Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 years |
| Amy Garabedian | F | - | 3 years | |
| Karen Wilson | F | 61 | 3 years | |
| Peter A. Schwartzman | M | - | 4 years | |
| Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 years |
| Stuart Ungar | M | 80 |
The Royal College of Physicians
| - |
| Lindsey Rolfe | M | 56 |
The Royal College of Physicians
| - |
| Pyarelal Baburam Tiwari | M | 77 |
The Royal College of Physicians
| - |
| Abdur Rahman Khan | M | 90 |
The Royal College of Physicians
| - |
| Peng Tiam Ang | M | 65 |
The Royal College of Physicians
| - |
| Sanjay Rajpara | M | - |
The Royal College of Physicians
| - |
| Matt Gysler | M | - |
The Royal College of Physicians
| - |
| Richard Bryce | M | 66 |
The Royal College of Physicians
| - |
| Alexander Macrae | M | 61 |
The Royal College of Physicians
| - |
| Kevin Chen | M | - |
The Royal College of Physicians
| - |
| Christopher Ball | M | - |
The Royal College of Physicians
| - |
| Tong Choon Cheo | M | 78 |
The Royal College of Physicians
| - |
| Olor'ogun Sonny Folorunso Kuku | M | 80 |
The Royal College of Physicians
| - |
| David J. Clark | M | 59 |
The Royal College of Physicians
| - |
| Michael Burgess | M | 61 |
The Royal College of Physicians
| - |
| Athasit Vejjajiva | M | 88 |
The Royal College of Physicians
| - |
| Mike Anderson | M | - |
The Royal College of Physicians
| - |
| Chun Kwan Chow | M | 69 |
The Royal College of Physicians
| 39 years |
| John Cullity | M | - |
The Royal College of Physicians
| - |
| Karen Atkin | M | 58 |
The Royal College of Physicians
| - |
| Ian Gourley | M | - |
The Royal College of Physicians
| - |
| Mark White | M | 57 |
The Royal College of Physicians
| - |
| Christopher Burton | M | - |
The Royal College of Physicians
| - |
| Huck Joo Tan | M | 56 |
The Royal College of Physicians
| 27 years |
| Ray Tallis | M | - |
The Royal College of Physicians
| - |
| Arvind Balakrishna Kasaragod | M | - |
The Royal College of Physicians
| - |
| Bipin Mistry | M | - |
The Royal College of Physicians
| - |
| Monica Shaw | M | 46 |
The Royal College of Physicians
| - |
| Richard Philipson | M | 60 |
The Royal College of Physicians
| - |
| Siew Mun Chu | M | 81 |
The Royal College of Physicians
| 50 years |
| Steve Knowles | M | - |
The Royal College of Physicians
| - |
| Lik Yuen Chan | M | 55 |
The Royal College of Physicians
| 29 years |
| Ravi Rao | M | 55 |
The Royal College of Physicians
| - |
| Edwin Tucker | M | 52 |
The Royal College of Physicians
| - |
| Alexandra Sinclair | M | - |
The Royal College of Physicians
| - |
| Dominic Smethurst | M | 50 |
The Royal College of Physicians
| - |
| Omar Khwaja | M | 54 |
The Royal College of Physicians
| 25 years |
| Man Yung Cheng | M | 74 |
The Royal College of Physicians
| 44 years |
| Suan Yew Lee | M | 91 |
The Royal College of Physicians
| - |
| Hilary McElwaine-Johnn | M | - |
The Royal College of Physicians
| - |
| Rudolf Kwan | M | 71 |
The Royal College of Physicians
| - |
| Ken Cunningham Cunningham | M | 71 |
The Royal College of Physicians
| - |
| John Bonnar | M | - |
The Royal College of Physicians
| - |
| Harry Solomon | M | 87 |
The Royal College of Physicians
| - |
| Richard Fuller | M | - |
The Royal College of Physicians
| - |
| Ka Wah Hui | M | 60 |
The Royal College of Physicians
| - |
| Martin Edwards | M | 68 |
The Royal College of Physicians
| - |
| Peter Richardson | M | 64 |
The Royal College of Physicians
| - |
| David Shapiro | M | 69 |
The Royal College of Physicians
| - |
| Herman Waldmann | M | - |
The Royal College of Physicians
| - |
| Kwok Yiu Wong | M | 65 |
The Royal College of Physicians
| 38 years |
| Richard Mason | M | - |
The Royal College of Physicians
| - |
| Ik King Tiong | M | 74 |
The Royal College of Physicians
| 47 years |
| Paul Blake | M | 76 |
The Royal College of Physicians
| - |
| Cheok Peng Lim | M | 77 |
The Royal College of Physicians
| 47 years |
| Henry Y. Pan | M | 77 |
The Royal College of Physicians
| - |
| Freda Lewis-Hall | M | 69 |
The Royal College of Physicians
| - |
| Lesley Russell | M | 63 |
The Royal College of Physicians
| 37 years |
| Andrew Allen | M | 57 |
The Royal College of Physicians
| - |
| Michael McDonald | M | - |
The Royal College of Physicians
| - |
| Hamish Alan Cameron | M | 70 |
The Royal College of Physicians
| - |
| Peter Dewis | M | - |
The Royal College of Physicians
| - |
| Warren Cooper | M | 71 |
The Royal College of Physicians
| - |
| Felicity Gabbay | M | 72 |
The Royal College of Physicians
| - |
| Preetinder Singh Joshi | M | 75 |
The Royal College of Physicians
| 46 years |
| Paul Kenna | M | - |
The Royal College of Physicians
| - |
| Stephen D. Wise | M | - |
The Royal College of Physicians
| - |
| Akshay Vaishnaw | M | 61 |
The Royal College of Physicians
| - |
| Ramesh Kancharla | M | 62 |
The Royal College of Physicians
| - |
| Kim Heung Tan | M | 62 |
The Royal College of Physicians
| 35 years |
| Simon Long | M | - |
The Royal College of Physicians
| - |
| Caroline Dumas | M | - |
The Royal College of Physicians
| - |
| Alan Keith Boyd | M | 70 |
The Royal College of Physicians
| - |
| Alan Suggett | M | 80 |
The Royal College of Physicians
| - |
| Samuel N. Marcus | M | - |
The Royal College of Physicians
| - |
| Emiko Terasaki | M | - |
The Royal College of Physicians
| 25 years |
| Swee Huat Phua | M | 70 |
The Royal College of Physicians
| - |
| Mehmood Khan | M | 66 |
The Royal College of Physicians
| - |
| Dawn Viveash | M | 68 |
The Royal College of Physicians
| - |
| Leo Kearns | M | - |
The Royal College of Physicians
| - |
| Kemal Malik | M | 61 |
The Royal College of Physicians
| - |
| Edwin Graham Meek | M | 76 |
The Royal College of Physicians
| - |
| Keng Hwang Teh | M | 71 |
The Royal College of Physicians
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David B. Johnston | M | 68 | 5 years | |
| Stephen J. Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 years |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| George Martin | M | 65 | 2 years | |
| Brent Hatzis-Schoch | M | 59 | 4 years | |
| Mark Enyedy | M | 60 | 8 years | |
| James Chopas | M | 58 | 3 years | |
| Jesper Høiland | M | 63 | 3 years | |
| Filippo Petti | M | 52 | 4 years | |
| Jose Carmona | M | 51 | 3 years | |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 83 | 83.00% |
| United States | 13 | 13.00% |
| Netherlands | 3 | 3.00% |
| Belgium | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Charles Q. Morris
- Personal Network